HOPE LIFE, together with ASC in the U.S., VAXON in France and other MedTech companies , and scientific research institutions such as Tsinghua University has established in-depth cooperation in biotechnology-centered R&D and transformation of drugs to treat cancers, diabetes, osteoarthritis, autoimmune diseases and premature ovarian failure, etc.
HOPE LIFE is experienced in the research and commercial application of skin health. With a full-dimensional skin test and one-on-one facial evaluation by experts, HOPE LIFE promises comprehensive repair and activation from the sebum membrane to the dermis layer.
In Shenzhen Hope Life Clinic, there are four departments: internal medicine, surgery, gynecology and dermatology. With a team of qualified and experienced medical experts, it has become a comprehensive modern medical institution diversified in disease diagnosis and treatment, disease prevention and healthcare.
RUZI biotech skincare products are originated from the profound achievements in the field of biotechnology for skincare. Led by the concept of “rejuvenation through biotech and scientific skincare approach”, RUZI only selects ingredients beneficial to your skin for skin rejuvenation.
HOPE LIFE has reached a long-term strategic cooperation with Applied StemCell Inc. (ASC for short, an American company) in exploring gene editing treatment of β-thalassemia.
HOPE LIFE and VAXON BioTech (a French company) have established a long-term strategic cooperation in the R&D and application of targeted therapies for drugs.
HOPE LIFE has cooperated with Reality (Shenzhen) BioTech Company by participating and investing in their co-development of gene drugs. The drug R&D project was started in 1998. Recombinant human glucokinase genes were used to develop gene drugs for treating type 2 diabetes. In the process, adenovirus and adeno-associated virus were adopted as carriers to deliver recombinant human glucokinase genes, and the results showed the expected safety and long-term effectiveness of glucose control in the pharmacodynamic study of animal models of diabetes. In this project, a cell bank has been constructed with the developed process for the production of plasmid strain bank, and it will soon enter the phase of pilot-scale production and toxicology research.
With regard to the future development of biotechnology, biopharmaceuticals and life sciences, a strategic partnership has been established among the National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital and Shenzhen Hope Life Technology Co., Ltd.
Shenzhen Hope Life Technology Co., Ltd. and Tsinghua University have reached a cooperation to seize the developing trend of biotechnology, biopharmaceuticals and life sciences.
HOPE LIFE has cooperated with Peking University Shenzhen Hospital to carry out the project for clinical research of β-thalassemia.
To carry out a project for the intervention treatment of stem cells on knee arthritis.
To boost the development of the biomedical industry and catch up with the pace of international biological research, HOPE LIFE and Shenzhen Third People's Hospital have reached a long term strategic partnership in the basic research and clinical transformation of biotechnology as well as the field of general health with a shared vision of complementary advantages and resource sharing.
HOPE LIFE has joined hands with Sino-sci Testing Tech of Primate Biomedical Research for the R&D and application of stem cell intervention treatment of knee arthritis.
HOPE LIFE has cooperated with Shenzhen Powerstar Gene Technology Co., Ltd. by participating and investing in their co-development of gene therapy for tumors with recombinant human 2IgB7-H3 gene. The R&D project was started in 2015, and breakthrough has been made thereafter. In the process, lentivirus was adopted as the carrier to deliver recombinant 2IgB7-H3 gene, and expected safety and remarkable effectiveness were observed in the in-vivo pharmacodynamic research based on tumor-bearing animal model. At present, the project is at the development stage of manufacturing lentiviral vectors.